Eli Lilly · Companies · The Inference

Health

Eli Lilly's retatrutide beat Ozempic head-to-head: 20.9% weight loss vs 9.4%, before Novo Nordisk reports

Lilly's retatrutide beat Ozempic's highest approved dose on blood sugar and cut more than twice the weight in a 1,298-patient Phase 3, published two days before Lilly's Q3 report. Novo's flagship franchise just lost its standard-of-care argument inside the window where payers and investors are repricing it.

October 28, 2026 · 2 min read

Health

Eli Lilly files 11 suits against retatrutide sellers before the drug even wins FDA approval

Eleven federal suits target sellers of an unapproved obesity drug before launch day. With Q3 earnings on October 29 showing 60% volume growth against a 13% price decline, Lilly is buying court protection for launch-year revenue.

October 26, 2026 · 3 min read

Health

Eli Lilly's olomorasib could win first-line KRAS lung cancer, and no one is trading the option

The ESMO data put Lilly's olomorasib on track to be the first targeted therapy sold into newly diagnosed KRAS G12C lung cancer, with Keytruda riding along in both combinations. The randomized proof lands next year, and nobody is trading the option yet.

October 25, 2026 · 3 min read

Eli LillyLLY

Market snapshot

Latest on Eli Lilly

Novo's Wegovy pill inherits a $32 billion franchise as a judge declines to block Lilly's ads

Eli Lilly's retatrutide beat Ozempic head-to-head: 20.9% weight loss vs 9.4%, before Novo Nordisk reports

Eli Lilly files 11 suits against retatrutide sellers before the drug even wins FDA approval

Eli Lilly's olomorasib could win first-line KRAS lung cancer, and no one is trading the option

Also mentioned in

Bristol Myers locked Tempus data through 2031 and led Pathos' $237 million round; Tempus reports November 2

Lilly raises guidance to $92 billion and hits a record close, while Novo Nordisk bets November on CagriSema

Ozempic blindness suits top 200 as Novo Nordisk spends DKK 11 billion on buybacks